Combining sCD163 with CA 19-9 Increases the Predictiveness of Pancreatic Ductal Adenocarcinoma

Liva K Stuhr; Kasper Madsen; Astrid Z Johansen; Inna M Chen; Carsten P Hansen; Lars H Jensen; Torben F Hansen; Kirstine Kløve-Mogensen; Kaspar R Nielsen; Julia S Johansen

doi:10.3390/cancers15030897

Combining sCD163 with CA 19-9 Increases the Predictiveness of Pancreatic Ductal Adenocarcinoma

Liva K Stuhr, Kasper Madsen, Astrid Z Johansen, Inna M Chen, Carsten P Hansen, Lars H Jensen, Torben F Hansen, Kirstine Kløve-Mogensen, Kaspar R Nielsen, Julia S Johansen^*

^*Corresponding author for this work

Abstract

The objective of this study was to evaluate the diagnostic and prognostic potential of soluble CD163 (sCD163) in patients with pancreatic ductal adenocarcinoma (PDAC). Preoperative serum samples from 255 patients with PDAC were analyzed for sCD163 using a commercially available enzyme-linked immunosorbent assay. The diagnostic value of sCD163 was evaluated using receiver operating characteristic (ROC) curves. The prognostic significance of sCD163 was evaluated by Cox regression analysis and Kaplan-Meier survival curves. sCD163 was significantly increased in patients with PDAC, across all stages, compared to healthy subjects (stage 1: p value = 0.033; stage 2-4: p value ≤ 0.0001). ROC curves showed that sCD163 combined with CA 19-9 had the highest diagnostic potential compared to sCD163 and CA 19-9 alone both in patients with local PDAC and patients with advanced PDAC. Univariate and multivariate analysis showed no association between sCD163 and overall survival. This study found elevated levels of circulating sCD163 in patients with PDAC, regardless of stage, compared to healthy subjects. This suggests that sCD163 may have a clinical value as a novel diagnostic biomarker in PDAC.

Original language	English
Article number	897
Journal	Cancers
Volume	15
Issue number	3
ISSN	2072-6694
DOIs	https://doi.org/10.3390/cancers15030897
Publication status	Published - 31 Jan 2023

Access to Document

10.3390/cancers15030897

Cite this

@article{43365909dcff46b3a5af6822530450e6,

title = "Combining sCD163 with CA 19-9 Increases the Predictiveness of Pancreatic Ductal Adenocarcinoma",

abstract = "The objective of this study was to evaluate the diagnostic and prognostic potential of soluble CD163 (sCD163) in patients with pancreatic ductal adenocarcinoma (PDAC). Preoperative serum samples from 255 patients with PDAC were analyzed for sCD163 using a commercially available enzyme-linked immunosorbent assay. The diagnostic value of sCD163 was evaluated using receiver operating characteristic (ROC) curves. The prognostic significance of sCD163 was evaluated by Cox regression analysis and Kaplan-Meier survival curves. sCD163 was significantly increased in patients with PDAC, across all stages, compared to healthy subjects (stage 1: p value = 0.033; stage 2-4: p value ≤ 0.0001). ROC curves showed that sCD163 combined with CA 19-9 had the highest diagnostic potential compared to sCD163 and CA 19-9 alone both in patients with local PDAC and patients with advanced PDAC. Univariate and multivariate analysis showed no association between sCD163 and overall survival. This study found elevated levels of circulating sCD163 in patients with PDAC, regardless of stage, compared to healthy subjects. This suggests that sCD163 may have a clinical value as a novel diagnostic biomarker in PDAC.",

author = "Stuhr, {Liva K} and Kasper Madsen and Johansen, {Astrid Z} and Chen, {Inna M} and Hansen, {Carsten P} and Jensen, {Lars H} and Hansen, {Torben F} and Kirstine Kl{\o}ve-Mogensen and Nielsen, {Kaspar R} and Johansen, {Julia S}",

year = "2023",

month = jan,

day = "31",

doi = "10.3390/cancers15030897",

language = "English",

volume = "15",

journal = "Cancers",

issn = "2072-6694",

publisher = "M D P I AG",

number = "3",

}

TY - JOUR

T1 - Combining sCD163 with CA 19-9 Increases the Predictiveness of Pancreatic Ductal Adenocarcinoma

AU - Stuhr, Liva K

AU - Madsen, Kasper

AU - Johansen, Astrid Z

AU - Chen, Inna M

AU - Hansen, Carsten P

AU - Jensen, Lars H

AU - Hansen, Torben F

AU - Kløve-Mogensen, Kirstine

AU - Nielsen, Kaspar R

AU - Johansen, Julia S

PY - 2023/1/31

Y1 - 2023/1/31

N2 - The objective of this study was to evaluate the diagnostic and prognostic potential of soluble CD163 (sCD163) in patients with pancreatic ductal adenocarcinoma (PDAC). Preoperative serum samples from 255 patients with PDAC were analyzed for sCD163 using a commercially available enzyme-linked immunosorbent assay. The diagnostic value of sCD163 was evaluated using receiver operating characteristic (ROC) curves. The prognostic significance of sCD163 was evaluated by Cox regression analysis and Kaplan-Meier survival curves. sCD163 was significantly increased in patients with PDAC, across all stages, compared to healthy subjects (stage 1: p value = 0.033; stage 2-4: p value ≤ 0.0001). ROC curves showed that sCD163 combined with CA 19-9 had the highest diagnostic potential compared to sCD163 and CA 19-9 alone both in patients with local PDAC and patients with advanced PDAC. Univariate and multivariate analysis showed no association between sCD163 and overall survival. This study found elevated levels of circulating sCD163 in patients with PDAC, regardless of stage, compared to healthy subjects. This suggests that sCD163 may have a clinical value as a novel diagnostic biomarker in PDAC.

AB - The objective of this study was to evaluate the diagnostic and prognostic potential of soluble CD163 (sCD163) in patients with pancreatic ductal adenocarcinoma (PDAC). Preoperative serum samples from 255 patients with PDAC were analyzed for sCD163 using a commercially available enzyme-linked immunosorbent assay. The diagnostic value of sCD163 was evaluated using receiver operating characteristic (ROC) curves. The prognostic significance of sCD163 was evaluated by Cox regression analysis and Kaplan-Meier survival curves. sCD163 was significantly increased in patients with PDAC, across all stages, compared to healthy subjects (stage 1: p value = 0.033; stage 2-4: p value ≤ 0.0001). ROC curves showed that sCD163 combined with CA 19-9 had the highest diagnostic potential compared to sCD163 and CA 19-9 alone both in patients with local PDAC and patients with advanced PDAC. Univariate and multivariate analysis showed no association between sCD163 and overall survival. This study found elevated levels of circulating sCD163 in patients with PDAC, regardless of stage, compared to healthy subjects. This suggests that sCD163 may have a clinical value as a novel diagnostic biomarker in PDAC.

UR - http://www.scopus.com/inward/record.url?scp=85147882315&partnerID=8YFLogxK

U2 - 10.3390/cancers15030897

DO - 10.3390/cancers15030897

M3 - Journal article

C2 - 36765852

VL - 15

JO - Cancers

JF - Cancers

SN - 2072-6694

IS - 3

M1 - 897

ER -

Combining sCD163 with CA 19-9 Increases the Predictiveness of Pancreatic Ductal Adenocarcinoma

Abstract

Access to Document

Other files and links

Fingerprint

Cite this